Jacob E T, Bar-Nathan N, Shapira Z, Gafni J
Arch Intern Med. 1979 Oct;139(10):1135-8.
Ten patients with familial Mediterranean fever (FMF) and histologically confirmed amyloidosis received cadaver kidney transplants for treatment of terminal renal disease. Colchicine, 1 mg daily, was included in the routine postoperative regimen from 1974 for amyloidotic patients. Graft and patient survival were compared with ten nonamyloidotic recipients of renal grafts matched for age, sex, type of allograft, and HLA compatibility. In the FMF group, five of ten grafts have survived from 20 to 64 months; in the control group, six of ten. While only recipients with functioning grafts survived in the FMF group, patient survival in the control group is eight of ten after one year. In all five FMF survivors, graft function is satisfactory, proteinuria is absent, and blood creatinine levels are normal. Amyloid involvement of an allograft was documented 16 months after transplantation in the only patient whose maintenance colchicine dosage had been reduced to 0.5 mg daily.
10例家族性地中海热（FMF）且经组织学确诊为淀粉样变性的患者接受了尸体肾移植，以治疗终末期肾病。自1974年起，淀粉样变性患者的术后常规治疗方案中包含每日1毫克秋水仙碱。将这10例患者的移植物和患者生存率与10例非淀粉样变性肾移植受者进行比较，后者在年龄、性别、同种异体移植物类型和HLA相容性方面相匹配。在FMF组中，10例移植物中有5例存活了20至64个月；在对照组中，10例中有6例。FMF组中只有移植肾功能良好的受者存活，而对照组1年后患者生存率为10例中的8例。在所有5例FMF存活者中，移植肾功能良好，无蛋白尿，血肌酐水平正常。在唯一一名维持秋水仙碱剂量减至每日0.5毫克的患者中，移植后16个月记录到同种异体移植物出现淀粉样变累及。
